Track market-moving stories before they get noisy

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2026 financial results before market opening on Tuesday, August 4, 2026. The Company will host a conference call and webcast at 9:00 a.m. Eastern Daylight Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q2 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A sli.

Posted by Defense World Staff on Jul 22nd, 2026

Fifth Third Bancorp boosted its holdings in Bruker Corporation (NASDAQ:BRKR – Free Report) by 4,058.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,135 shares of the medical research company’s stock after purchasing an additional 55,761 shares during the quarter. Fifth Third Bancorp’s holdings in Bruker were worth $2,064,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Orbis Allan Gray Ltd acquired a new position in Bruker in the second quarter valued at $192,735,000. Price T Rowe Associates Inc. MD increased its position in Bruker by 2,963.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock valued at $111,488,000 after acquiring an additional 2,289,269 shares during the period. AQR Capital Management LLC raised its stake in Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after acquiring an additional 1,850,215 shares during the last quarter. Franklin Resources Inc. lifted its position in Bruker by 317.7% during the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock worth $108,796,000 after acquiring an additional 1,756,460 shares during the period. Finally, Millennium Management LLC grew its stake in shares of Bruker by 222.6% in the 4th quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company’s stock valued at $86,663,000 after purchasing an additional 1,269,316 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Price Performance Shares of NASDAQ BRKR opened at $60.43 on Wednesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55. Bruker Corporation has a one year low of $28.53 and a one year high of $64.54. The firm has a market capitalization of $9.20 billion, a P/E ratio of -251.79, a PEG ratio of 1.80 and a beta of 1.29. The company’s fifty day moving average is $55.29 and its two-hundred day moving average is $46.03.

Bruker (NASDAQ:BRKR – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The firm had revenue of $823.40 million during the quarter, compared to analysts’ expectations of $795.62 million. During the same quarter last year, the business earned $0.47 earnings per share. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts forecast that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Announces Dividend The company also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were issued a $0.05 dividend. The ex-dividend date was Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker’s dividend payout ratio is currently -83.33%.

Analyst Upgrades and Downgrades A number of equities analysts recently weighed in on BRKR shares. JPMorgan Chase & Co. lifted their price objective on shares of Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, June 8th. Barclays lifted their target price on shares of Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Leerink Partners increased their price target on shares of Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Finally, TD Cowen restated a “hold” rating on shares of Bruker in a research report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $56.79.

View Our Latest Stock Report on BRKR

Bruker Profile (Free Report)

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

See Also Five stocks we like better than Bruker Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEFifth Third Bancorp Invests $2.49 Million in Palvella Therapeutics, Inc. $PVLA

NEXT HEADLINE »Fifth Third Bancorp Has $2.09 Million Stake in National Vision Holdings, Inc. $EYE

Key Takeaways Bruker shares rose 50.3% in a year, aided by strong BSI NANO growth and solid bookings. Bruker saw AI-driven demand lift metrology tool orders, with Semi Metrology above $300M revenues. Bruker cut long-term debt to $1.66B and generated $47.0M in first-quarter free cash flow. Bruker Corporation (BRKR - Free Report) has witnessed strong momentum over the past year. Shares of the company have risen 50.3%, outperforming the industry’s 42.5% growth. The S&P 500 composite has increased 28.2% during the same time frame.

With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.

Bruker designs and manufactures proprietary life science and materials research systems and associated products. Bruker is located at 90 regions across the globe. It has direct sales forces employed through North America, Europe, Japan, Asia Pacific and Australia. 

The company reports through four segments — Bruker Scientific Instruments (“BSI”) BioSpin, BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection), BSI NANO, and Bruker Energy & Supercon Technologies (“BEST”). 

Factors Favoring BRKR’s Share Price GrowthBruker’s share price is trending upward, prompted by its strong growth of BSI NANO segment. Within this, the company highlighted organic bookings growth above expectations in the first quarter of 2026, with BSI book-to-bill above 1.0X for the third consecutive quarter. 

AI-driven demand for memory chips and advanced packaging continued to drive orders for metrology tools. Semi Metrology has grown into a business generating more than $300 million in annual revenues.

Investors are currently focused on the company’s strong market share gain in preclinical imaging (PCI) space. In the first quarter of 2026, BioSpin reported acceptance of an 18 Tesla preclinical MRI system, reinforcing Bruker’s positioning at the high end of the installed base. 

Over time, broader adoption of imaging in translational research can support system demand and service pull-through, particularly as new hyperpolarization and workflow enhancements increase the utility of MRI-based platforms.

From a solvency viewpoint, cash and cash equivalents totaled $133.4 million at the end of the first quarter of 2026 compared with $298.8 million at the close of 2025. The company repaid $181.3 million of long-term debt, reducing the balance to $1.66 billion as of March 31, 2026, from $1.85 billion at year-end 2025. This reflects the debt paydown and working capital usage, including higher inventories. 

Net leverage declined to 2.9X at the end of the quarter. The bullish 2026 outlook supports continued investments in business. Bruker generated $71.2 million of operating cash flow in the first quarter and spent $24.2 million on capital expenditures, resulting in $47.0 million of free cash flow.

Image Source: Zacks Investment Research

Factors That May Offset BRKR’s GainsBruker’s business remains vulnerable to tariffs and currency effects, which influenced year-over-year results in the first quarter of 2026. Adjusted operating margin declined to 10.2% from 12.7% in the year-ago period, partly tied to tariff-related changes and foreign exchange. 

In the first quarter of 2026, foreign exchange reduced adjusted EPS by $0.05. For full-year 2026, management continues to assume an EPS currency impact of about 8%, which can limit comparability and keep consensus estimates sensitive to rate moves. 

The company also faces competition in the life science tools, metrology and diagnostics markets from larger peers that benefit from broad installed bases and significant scale in R&D and distribution. In a softer demand setting for academic and industrial customers, competitive discounting and mix shifts can reduce returns from growth initiatives.

A Look at BRKR’s EstimatesThe Zacks Consensus Estimate for 2026 EPS has remained unchanged at $2.12 in the past 30 days.

The company has an estimated long-term EPS growth rate of 14.8%, in line with the industry’s growth rate. 

Stocks to ConsiderSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) . 

Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.

GMED carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.

Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.

MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operati.

On April 17, 2026, Bruker Corp (BRKR) shares rose 4.5% today, bringing the current price to $40.70. The stock has experienced a 52-week range of $28.53 to $56.2

A few weeks ago, a research paper out of MIT (the college) crossed my desk that most investors would have ignored.

It was about worms.

Specifically, it was about a team that had successfully mapped the entire brain of a microscopic worm — every neuron, every connection. 

Then it laid out what it would take to scale that process from a worm… to a mouse… and eventually, to a human.

Now, here’s where things get interesting for us.

For decades, mapping the human brain has been one of science’s biggest challenges. And while we’re still years away from a definitive solution, we’re starting to see the missing piece fall into place that could break the whole field wide open: brain-computer interfaces.

These are systems that allow the brain to communicate directly with machines — turning thought into action and speech.

Right now, the headlines focus on major players like Elon Musk’s Neuralink— buffeted by twelve patients, a $9B valuation, and IPO rumors.

Sam Altman also committed $250 million to his own brain-chip startup earlier this year.

The reporting surrounding these companies often leans toward the dramatic: the merging of mind and machine, the next frontier of artificial intelligence, the possibility of restoring lost functions or even augmenting human cognition. 

It is a story that lends itself to headlines. But it is also, in some ways, a misleading one. The visible pieces of this emerging field — the implants, the interfaces — represent only its final layer.

What they’re hiding is a much larger system that must exist before they can function in any meaningful way.

This is where the real opportunity lies for us. And in order to understand, we need to dig deeper than the headlines…

The Critical Systems Holding This Breakthrough Back Once I got over my initial excitement after reading the report and considering what it might mean, I did what traders do: I moved straight to the supply chain. 

The MIT thesis, perhaps unintentionally, offers a map of this growing system. 

It identifies several areas that must advance together: structural imaging, which captures the physical wiring of the brain; functional imaging, which records activity; molecular analysis, which explains how neurons behave; and computational infrastructure, which integrates and simulates these layers. 

Each of these parts has made significant progress in isolation. What’s new is the recognition that they are dependent on each other so that major progress in one without the others is unlikely.

This interdependence means that what we’re really looking at is a set of bottlenecks that are overlooked in the broader narrative.

This is exactly the kind of shift we focus on inside the Masters in Trading Challenge — learning how to move past the obvious story and identify where the real edge sits before it becomes consensus.

It’s not about predicting the headline outcome. It’s about understanding what has to happen underneath it—and positioning early. If you want to see exactly how we approach setups like this, you can learn more about the Masters in Trading Challenge here.

One of the clearest examples of this shows up in imaging. Imaging a brain at sufficient resolution is not simply a matter of improving a single machine. It requires scaling entire systems — microscopes, data pipelines, processing algorithms — by orders of magnitude.

The thesis suggests that even mapping a mouse brain would require dozens of high-throughput electron microscopes operating continuously for years.

And for a human brain? That demands far more extensive infrastructure that’s currently lacking.

The Next “Genome Project” Is Already Taking Shape Building these systems are not incremental challenges. They resemble, in scale and coordination, the kinds of efforts more commonly associated with large public works or scientific “moonshots.” 

The Human Genome Project – the effort to map all human DNA that turned biology into a data-driven science and made genetic research dramatically faster and cheaper – is often cited as an analogy. 

When it was all said and done, that project required more than a decade and billions of dollars to complete. 

Brain emulation, if pursued at a similar scale, would likely demand comparable levels of investment and collaboration.

If the history of technological change offers any guidance, it is that the most transformative shifts rarely occur where attention is first directed. 

They unfold, instead, in the spaces beneath the surface, where small advances accumulate until they alter what is possible.

The sensors. The chips. The imaging systems.

That’s where capital is starting to flow.

Right now, I’m tracking 14 names tied to this theme — 10 public, 4 private.

In today’s essay, I’m breaking down all fourteen names across three buckets:

Two to start with today Eight to build deeper exposure And four private companies to watch as they approach public markets. Let’s dive in…

Bucket 1 – Start Here If you only buy two names from this basket, start here.

Butterfly Network (BFLY): ~$500M market cap BFLY produces handheld, chip-based ultrasound devices used in brain imaging. And unlike some of the other names on this list, this early-stage player is already bringing in sound business.

Last quarter, BFLY turned profitable for the first time, with revenue growing 41% year-over-year to $31.5M.

That momentum is only increasing as BFLY secures more contracts around its signature tech. Its ultrasound chip is licensed into Forest Neurotech, an Eric Schmidt-backed brain-computer interface project – and that’s just one key partnership among many.

At a $500M market cap – with real revenue and BCI exposure – the risk/reward looks cleaner than most.

How I’d Play It Start a position and add on pullbacks to support. This isn’t a moonshot—it’s a functioning business with an underappreciated catalyst.

Quantum-Si (QSI): ~$194M market cap This is the asymmetric bet. It offers the only commercial single-molecule protein sequencer currently available on the market.

The MIT research identifies protein sequencing as a gating technology for brain mapping. Right now, this is the only U.S.-listed way to access it. With revenue at just $2.4 million, this is a company firmly in its earliest stages with massive growth ahead.

How I’d Play It Keep position size small. Treat it like a call option, not a core holding. If the thesis works, the upside could be significant. If not, downside risk is real.

Bucket 2 – Add These to Go Deeper These names round out the basket if you want broader exposure. It’s a mix of small-cap volatility and large-cap stability.

Hyperfine (HYPR): $127M market cap HYPR provides the only FDA-cleared portable brain MRI system on the market – its Swoop device, which brings imaging directly to the bedside.

HYPR’s reach is beginning to expand beyond the U.S. Just this year, the startup received approval in India to sell its devices, opening up a large new market.

HYPR is one of the smallest small-caps on this list. And it always trades on news.

With that approval and a surge in value since March, HYPR remains one of the best early land-grab opportunities in this basket.

How I’d Play It Add HYPR for direct brain imaging exposure. Watch upcoming guidance for signs of international traction.

NVIDIA (NVDA): $5.6T market cap Most investors own NVIDIA for AI, but few connect it to the brain race. That’s about to change.

NVIDIA’s Holoscan is an important application in the brain imaging race. For those who don’t know, it’s an AI-enabled sensor processing platform designed for real-time edge computing that can be deployed in various use cases – from security applications to the medical field.

Many of the top BCI players are building their tech on top of NVIDIA’s Holoscan. BCI manufacturer Synchron’s interface runs on NVIDIA Holoscan. And another BCI startup, Merge Labs, is expected to train models on its chips.

Regardless of which platform wins, NVIDIA sits upstream.

How I’d Play It If you already own it, you have exposure. If not, this is another reason to consider it.

Micron (MU): $560B market cap This is the memory bottleneck trade. Compute has scaled far faster than memory over the last three decades. That gap is becoming critical for both AI and brain emulation.

Micron is the clearest U.S.-listed play on high-bandwidth memory. And with so many clients for its chips already being participants in the modern brain race, this stock is one of the best ways to gain early exposure today.

How I’d Play It It’s cyclical. Look to buy on weakness.

Medtronic (MDT): $100B market cap Medtronic partnered with Precision Neuroscience, gaining exposure to BCIs without building the technology internally.

That’s a massive edge in a market where the biggest BCI makers are still dealing with major cost overruns and costly implementation failures.

Medtronic is already a giant in the space. With this partnership in place, MDT represents a more conservative way to trade the theme.

How I’d Play It Useful for portfolios seeking income and lower volatility with some upside optionality.

Nautilus Biotechnology (NAUT): $331.6M market cap This stock is a complementary play to QSI. NAUT approaches protein sequencing differently but targets the same bottleneck. And a recent partnership with Baylor College adds early validation.

How I’d Play It Smaller position than QSI. Treat both as a paired bet.

Bruker (BRKR): $5.56B market cap This is a “picks and shovels” name that’s been setting off my UOA Monitor for weeks.

In fact, I just recently recommended the trade on Masters in Trading LIVE  as the perfect way to gain early exposure to the BCI trend.

This stock already has massive penetration in the space. Its microscopy systems are used across leading brain-mapping labs. It’s a medium-sized player with a lot of room to run.

How I’d Play It A more stable position relative to smaller biotech names.

Thermo Fisher (TMO): $174.5B market cap One of only two companies globally producing the high-throughput electron microscopes used in connectomics research. A long-term compounder.

How I’d Play It A steady, long-duration hold with lower volatility.

Broadcom (AVGO): $2.01T market cap AVGO provides custom AI chips and networking infrastructure for hyperscalers. While not a direct BCI play, it supports the systems that make brain-scale computation possible.

How I’d Play It Similar to NVIDIA—core infrastructure exposure.

Bucket 3 – Watching, But Not Yet Public These are private companies to monitor for IPO activity. When one files, expect ripple effects across the entire basket.

Neuralink
Private: ~$9B valuation Elon Musk’s BCI company has twelve patients implanted. So far, it’s one of the most regulatorily compliant and well capitalized names in the space, already backed by FDA Breakthrough Device designation.

How I’d Play It Not publicly tradable yet. When it files, expect rapid repricing across related equities.

Synchron
Private: Pre-IPO Synchron offers a less invasive interface delivered via the jugular vein – all backed by Jeff Bezos and Bill Gates. As I alluded to at the top, Synchron also has several major partnerships in place with companies like NVIDIA and Apple Vision Pro.

HOW I’D PLAY IT Watch for IPO filing. Potentially lower-risk than Neuralink due to its approach.

Precision Neuroscience
Private: Pre-IPO Precision is working on a surface-level brain interface developed by a former Neuralink engineer. And it just recently received FDA clearance and partnered with Medtronic – all great signs as it works its way to a potential IPO.

How I’d Play It Indirect exposure exists through Medtronic. Consider direct exposure if it goes public.

Colossal Biosciences
Private: Pre-IPO Colossal is connected to Harvard geneticist George Church. While it’s not a pure BCI play, the company is part of a broader biotech ecosystem that could intersect with neural research.

How I’d Play It Highly speculative. Monitor for developments.

One last note: I’m long QSI. I do not currently hold the other names listed here. This reflects my research and watchlist—not a recommendation to buy or sell any security. Small-cap stocks in this space can be highly volatile. Do your own research and consult a licensed professional before investing.

What Happens Next History shows that when a complex problem becomes a matter of engineering—when it can be broken down into discrete constraints—capital flows to the solutions. And that all happens often before the broader narrative fully takes hold.

Today, much of this ecosystem remains underfollowed and, in some cases, mispriced relative to its potential role in the broader shift.

That won’t last.

As progress in these underlying technologies becomes more visible — through partnerships, breakthroughs, and eventually public listings — the market will connect the dots.

When it does, the repricing is unlikely to be gradual.

For investors, the takeaway is straightforward: Focus less on the outcome and more on what must happen for that outcome to exist.

That’s where the opportunity is today.

And if you’re interested in learning more about the system that discovered all these names…

That knowledge is waiting for you inside the Masters in Trading Options Challenge.

The Challenge is where we take everything you’ve learned in my articles and daily LIVEs — fixed risk, thesis-driven exits, laddered entries, defined-duration trades, and emotional discipline — and put it into practice in a structured, step-by-step environment.

For seven days, we walk through the foundations of real options trading the way I learned them on the trading floor. You’ll learn exactly how I think, exactly how I build trades, and exactly how I manage both the winners and the losers.

Just click here to check out what the Masters in Trading Options Challenge has in store for you.

Remember, the creative trader wins.

Jonathan Rose,

Founder, Masters in Trading

P.S. In a recent beta test, TradeSmith CEO Keith Kaplan’s new signals-based approach produced gains in just days — not months. Now, for a limited time, you can explore the same system yourself and see what it’s flagging right now across the market. To get a firsthand look at the same AI Signals system Keith uses — including the top signals of the day and detailed data on any stock you search — watch the full presentation here.

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three months ended March 31, 2026.

Frank H. Laukien, Bruker’s President and CEO, commented: “While US academic demand, tariff and currency headwinds still pressured our first quarter results, our Q1 financial performance came in ahead of expectations. We are encouraged that our first quarter BSI segment bookings grew organically at a high single digit percentage, and our BSI book-to-bill ratio was again greater than 1.0x. Healthy bookings trends included solid academic orders for our post-genomic research solutions from outside the US, strong AI-driven demand in semiconductor metrology and in SciY laboratory software, bookings strength in industrial research tools and security detection systems.”

He continued: “Importantly, we have introduced impactful new products and solutions at recent scientific and medical conferences, further strengthening our leadership position in NMR, leading the way in spatial biology, and innovating in microbiology and molecular diagnostics. With increased visibility, we reconfirm our FY26 guidance, and we expect a return to organic revenue growth in Q2. All in, Bruker remains poised to deliver significant operating margin expansion and double-digit EPS growth in FY2026.”

First Quarter 2026 (Q1-26) Financial Results

Bruker’s revenues for the first quarter of 2026 were $823.4 million, an increase of 2.7% compared to $801.4 million in the first quarter of 2025. In Q1-26, revenues decreased organically by 4.4% yoy, while growth from acquisitions was 2.6%, and foreign currency translation had a favorable impact of 4.5% yoy.

Q1-26 Bruker Scientific Instruments (BSI) revenues of $759.8 million increased 2.1% yoy, with organic revenue decreasing by 5.0%. Q1-26 Bruker Energy & Supercon Technologies (BEST) revenues of $66.9 million increased 12.8% yoy, with an organic revenue increase of 3.0%, net of intercompany eliminations.

Q1-26 GAAP operating income was $10.2 million, compared to GAAP operating income of $31.8 million in the first quarter of 2025. Bruker's Q1-26 non-GAAP operating income was $84.2 million, compared to $101.7 million in the first quarter of 2025, and Q1-26 non-GAAP operating margin was 10.2%, compared to 12.7% in the first quarter of 2025.

Q1-26 GAAP diluted earnings per share was $0.02, compared to diluted earnings per share of $0.11 in the first quarter of 2025. Q1-26 non-GAAP diluted EPS was $0.31, compared to $0.47 in the first quarter of 2025.

Reconfirming Previous Fiscal Year 2026 (FY26) Financial Outlook

Bruker continues to expect FY26 revenues of $3.57 to $3.60 billion, compared to FY25 revenues of $3.44 billion, with 4% to 5% year-over-year reported revenue growth, including:

Organic revenue growth of 1% to 2%, M&A revenue growth contribution of approximately 1.5%, and Foreign currency translation revenue tailwind of approximately 1.5% Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15, compared to $1.83 in FY25, an increase of 15% to 17% year-over-year. This includes a currency headwind of approximately $0.15, or 8%, implying constant exchange rate (CER) non-GAAP EPS growth of 23% to 25% yoy.

Our FY26 revenue and non-GAAP EPS guidance is based on foreign currency exchange rates as of March 31, 2026.

For the Company’s outlook for 2026 organic revenue growth, M&A revenue growth, constant exchange rate revenue growth, and constant exchange rate non-GAAP EPS growth, and non-GAAP EPS, each of which are forward-looking non-GAAP measures, we are not able to provide without unreasonable effort the most directly comparable GAAP financial measures, or reconciliations to such GAAP financial measures on a forward-looking basis. Please see “Use of Non-GAAP Financial Measures” below for a description of items excluded from our expected non-GAAP EPS.

Quarterly Earnings Call

Bruker will host a conference call and webcast to discuss its financial results, business outlook, and related corporate and financial matters today, May 6, 2026, at 8:00 am Eastern Daylight Time. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2026 Earnings Webcast” hyperlink. A slide presentation will be referenced during the webcast and will be posted to our Investor Relations website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international) and referencing “Bruker’s First Quarter 2026 Earnings Conference Call”.

Bruker is enabling investors to pre-register for the earnings conference call so that they can expedite their entry into the call and avoid the need to wait for a live operator. In order to pre-register for the call, investors can visit https://dpregister.com/sreg/10208837/103f221d07a and enter their contact information. Investors will then be issued a personalized phone number and PIN to dial into the live conference call. Individuals can pre-register any time prior to the start of the conference call.

A telephone replay of the conference call will be available by dialing 1-855-669-9658 (U.S. toll free) or +1-412-317-0088 (international) and entering replay access code: 6572958. The replay will be available beginning one hour after the end of the conference call through June 6, 2026.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in specialty diagnostics, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Use of Non-GAAP Financial Measures

To supplement our consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (GAAP), we use the following non-GAAP financial measures: non-GAAP gross profit; non-GAAP gross profit margin; non-GAAP operating income; non-GAAP operating income margin; non-GAAP SG&A expense; non-GAAP interest and other income (expense), net; non-GAAP profit before income taxes; non-GAAP income tax rate; non-GAAP net income and non-GAAP diluted earnings per share. These non-GAAP measures exclude costs related to restructuring actions, impairments, acquisition and related integration expenses, amortization of acquired intangible assets, and other non-operational costs.

We also may refer to CER currency revenue growth, CER non-GAAP EPS growth, and free cash flow which are also non-GAAP financial measures. We define the term CER currency revenue as GAAP revenue excluding the effect of changes in foreign currency translation rates. We define the term CER EPS as non-GAAP EPS excluding the effect of changes in foreign currency translation rates. We define free cash flow as net cash provided by operating activities, less additions to property, plant, and equipment. We believe free cash flow is a useful measure to evaluate our business because it indicates the amount of cash generated after additions to property, plant, and equipment that is available for, among other things, acquisitions, investments in our business, repayment of debt and return of capital to shareholders.

The presentation of these non-GAAP financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP and may be different from non-GAAP financial measures used by other companies, and therefore, may not be comparable among companies. We believe these non-GAAP financial measures provide meaningful supplemental information regarding our performance. However, we urge investors to review the reconciliation of these financial measures to the comparable GAAP financial measures included in the accompanying tables, and not to rely on any single financial measure to evaluate our business. Specifically, management believes that the non-GAAP measures mentioned above provide relevant and useful information which is widely used by analysts, investors and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance.

We use these non-GAAP financial measures to evaluate our period-over-period operating performance because our management believes this provides a more comparable measure of our continuing business by adjusting for certain items that are not reflective of the underlying performance of our business. These measures may also be useful to investors in evaluating the underlying operating performance of our business and forecasting future results. We regularly use these non-GAAP financial measures internally to understand, manage, and evaluate our business results and make operating decisions. We also measure our employees and compensate them, in part, based on certain non-GAAP measures and use this information for our planning and forecasting activities.

Additional information relating to the non-GAAP financial measures used in this press release and reconciliations to the most directly comparable GAAP financial measures are provided in the tables accompanying this press release following our GAAP financial statements.

With respect to our outlook for 2026 non-GAAP organic revenue, non-GAAP M&A revenue, and non-GAAP EPS, we are not providing the most directly comparable GAAP financial measures or corresponding reconciliations to such GAAP financial measures on a forward-looking basis, because we are unable to predict with reasonable certainty certain items that may affect such measures calculated and presented in accordance with GAAP without unreasonable effort. Our expected non-GAAP organic revenue and EPS ranges exclude primarily the future impact of restructuring actions, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments. These reconciling items are uncertain, depend on various factors outside our management’s control and could significantly impact, either individually or in the aggregate, our future revenues and EPS presented in accordance with GAAP.

Forward-Looking Statements

Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our fiscal year 2026 and beyond financial outlook, our outlook for reported revenue growth, organic revenue growth, M&A revenue growth contributions, CER currency revenue growth, margin improvements, foreign currency translation revenue impact, EPS, non-GAAP EPS, and CER Non-GAAP EPS growth; effects of academic market and tariff dynamics on our future financial results and our ability to mitigate such effects in the future; management’s expectations for the impact of foreign currency and acquisitions; the effects of our expanded cost savings initiatives; and for future financial and operational performance and business outlook; future economic conditions; and statements found under the “Use of Non-GAAP Financial Measures” section of this release. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, (1) the length and severity of any recession and the impact on global economic conditions, (2) the impact of supply chain challenges, including inflationary pressures, (3) the impact of geopolitical instability and tensions and any sanctions, including any reduction in natural gas exports from Russia resulting from the ongoing conflict with Ukraine and resulting market disruptions, such as higher prices for and reduced availability of key metals used in our products, (4) the conflict in Israel, Palestine and surrounding areas and hostilities in the Middle East, including heightened tensions in Iran, and the possible expansion of such conflicts and potential geopolitical consequences and global instability, (5) the ongoing tensions between the United States and China, tariff increases or uncertainties and trade policy changes and restrictions, and the increasing potential of conflict involving countries in Asia that are critical to our supply chain operations, such as Taiwan and China, (6) continued volatility in the capital markets, (7) the impact of increased interest rates, (8) the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, (9) our restructuring and cost-control initiatives, changing technologies, product development and market acceptance of our products, (10) the cost and pricing of our products, manufacturing and outsourcing, competition, dependence on collaborative partners, key suppliers and third party distributors, capital spending and government funding policies, (11) changes in governmental regulations, intellectual property rights, and litigation, (12) exposure to foreign currency fluctuations, (13) the impact of foreign currency exchange rates, (14) our ability to service our debt obligations and fund our anticipated cash needs, (15) the effect of a concentrated ownership of our common stock, (16) the loss of key personnel, (17) payment of future dividends, (18) the impact (if any) of macroeconomic issues, including uncertainties related to trade policies or tariff regulations, and (19) other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2025, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by applicable law.

Bruker Corporation

PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

(in millions, except per share data)

  Three Months Ended
March 31,

2026

2025

Revenue

$

823.4

$

801.4

Cost of revenue

443.6

410.2

Gross profit

379.8

391.2

Operating expenses:

Selling, general and administrative

242.1

225.4

Research and development

101.3

97.1

Other charges, net

26.2

36.9

Total operating expenses

369.6

359.4

Operating income

10.2

31.8

Interest and other income (expense), net

11.7

(6.7

)

Income before income taxes, equity in (losses) income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries (a)

21.9

25.1

Income tax provision

2.5

8.7

Equity in (losses) income of unconsolidated investees, net of tax

(3.7

)

0.4

Consolidated net income

15.7

16.8

Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries

1.3

(0.6

)

Net income attributable to Bruker Corporation

$

14.4

$

17.4

Dividends on Series A Mandatory Convertible Preferred Stock

10.9

—

Net income attributable to Bruker Corporation common shareholders

$

3.5

$

17.4

Net income per common share attributable to Bruker Corporation common shareholders:

Basic

$

0.02

$

0.11

Diluted

$

0.02

$

0.11

Weighted average common shares outstanding:

Basic

152.2

151.6

Diluted

152.7

151.9

  a) On subsequent pages this is referred to as “Profit before income tax”.

Bruker Corporation

REVENUE

(unaudited and in millions)

  Three Months Ended
March 31,

2026

2025

Revenue by Segment:

Bruker BioSpin

$

197.5

$

207.8

Bruker CALID

316.3

280.1

Bruker Nano

246.0

256.6

BSI Revenue Total

759.8

744.5

BEST

66.9

59.3

Eliminations

(3.3

)

(2.4

)

Total revenue

$

823.4

$

801.4

Revenue by End Customer Geography:

United States

$

221.9

$

217.4

Europe

321.6

285.2

Asia Pacific

208.7

232.6

Other

71.2

66.2

Total revenue

$

823.4

$

801.4

Bruker Corporation
RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES
(unaudited and in millions, except per share data)

The tables below present the GAAP to Non-GAAP reconciliation for the three months ended March 31, 2026, and March 31, 2025, respectively, for the following measures: Gross Profit and Gross Profit Margin; Selling, General and Administrative (“SG&A”) Expenses; Operating Income and Operating Income Margin; Interest and Other Income (Expense), net; Profit before Income Taxes; Net Income Attributable to Bruker Corporation Common Shareholders; Diluted net income per common share; and Income Tax rate.

Gross Profit

Gross Profit Margin

SG&A Expenses

Operating Income

Operating Income Margin

Interest and other income (expense), net

Profit before income tax (a)

Net Income attributable to Bruker Corporation Common Shareholders

Diluted net income per common share

Income Tax Rate

Three Months Ended March 31, 2026:

GAAP

$

379.8

46.1

%

$

242.1

$

10.2

1.2

%

$

11.7

$

21.9

$

3.5

$

0.02

11.4

%

Non-GAAP adjustments:

Restructuring costs

9.5

1.2

%

—

17.8

2.2

%

—

17.8

17.8

0.12

—

Acquisition-related costs

3.4

0.4

%

—

7.5

0.9

%

—

7.5

7.5

0.05

—

Purchased intangibles amortization

16.7

2.0

%

(15.7

)

32.5

3.9

%

—

32.5

32.5

0.21

—

Intangible assets impairment charges

0.7

0.1

%

—

2.7

0.3

%

—

2.7

2.7

0.02

—

Gain on remeasurement of previously held equity interest

—

—

—

—

—

(12.2

)

(12.2

)

(12.2

)

(0.08

)

Investments related adjustments

—

—

—

—

—

(1.2

)

(1.2

)

(1.2

)

(0.01

)

—

Lease and fixed asset impairment charges

1.8

0.2

%

—

12.7

1.5

%

—

12.7

12.7

0.08

—

Other costs

(0.1

)

—

—

0.8

0.2

%

—

0.8

0.8

0.01

—

Tax effect of above Non-GAAP adjustments

—

—

—

—

—

—

—

(20.3

)

(0.13

)

16.2

%

Equity in income (losses) of unconsolidated investees, net of tax

—

—

—

—

—

—

—

3.7

0.02

—

Noncontrolling interests related to non-GAAP adjustments

—

—

—

—

—

—

—

(0.5

)

—

—

Total Non-GAAP adjustments

32.0

3.9

%

(15.7

)

74.0

9.0

%

(13.4

)

60.6

43.5

0.29

16.2

%

Non-GAAP

$

411.8

50.0

%

$

226.4

$

84.2

10.2

%

$

(1.7

)

$

82.5

$

47.0

$

0.31

27.6

%

Three Months Ended March 31, 2025:

GAAP

$

391.2

48.8

%

$

225.4

$

31.8

4.0

%

$

(6.7

)

$

25.1

$

17.4

$

0.11

34.7

%

Non-GAAP adjustments:

Restructuring costs

2.6

0.3

%

—

10.2

1.3

%

—

10.2

10.2

0.07

—

Acquisition-related costs

2.3

0.3

%

—

8.6

1.1

%

—

8.6

8.6

0.06

—

Purchased intangibles amortization

14.0

1.7

%

(13.1

)

27.3

3.4

%

—

27.3

27.3

0.18

—

Acquisition-related litigation charges

—

—

—

18.6

2.3

%

—

18.6

18.6

0.12

—

Investments related adjustments

—

—

—

—

—

2.0

2.0

2.0

0.01

—

Other costs

0.8

0.2

%

—

5.2

0.6

%

—

5.2

5.2

0.03

—

Tax effect of above Non-GAAP adjustments

—

—

—

—

—

—

—

(18.2

)

(0.11

)

(0.6

)%

Other Discrete Items

—

—

—

—

—

—

—

—

—

(6.4

)%

Equity in income (losses) of unconsolidated investees, net of tax

—

—

—

—

—

—

—

(0.4

)

—

—

Total Non-GAAP adjustments

19.7

2.5

%

(13.1

)

69.9

8.7

%

2.0

71.9

53.3

0.36

(7.0

)%

Non-GAAP

$

410.9

51.3

%

$

212.3

$

101.7

12.7

%

$

(4.7

)

$

97.0

$

70.7

$

0.47

27.7

%

Bruker Corporation
RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES - Continued
(unaudited and in millions, except per share data)

The tables below present the GAAP to Non-GAAP reconciliation for weighted average common shares outstanding (Diluted), CER currency revenue, organic revenue, and free cash flow:

Three Months Ended
March 31,

2026

2025

GAAP Weighted Average Common Shares Outstanding (Diluted)

152.7

151.9

Stock options, restricted stock units, and employee stock purchase plan

—

—

Series A Mandatory Convertible Preferred Stock (a)

—

—

Non-GAAP Weighted Average Common Shares Outstanding (Diluted)

152.7

151.9

Total Bruker

Bruker Scientific Instruments (a)

BEST

Three Months Ended March 31,

2026

yoy growth (c)

2025

2026

yoy growth (c)

2025

2026

yoy growth (c)

2025

GAAP revenue

$

823.4

2.7%

$

801.4

$

759.8

2.1%

$

744.5

$

63.6

11.8%

$

56.9

Effect of changes in foreign currency translation rates

36.6

(10.4

)

31.6

(9.2

)

5.0

(1.2

)

Non-GAAP CER currency revenue

786.8

(1.8)%

811.8

728.2

(2.2)%

753.7

58.6

3.0%

58.1

Acquisitions (b)

20.8

69.2

20.8

69.2

-

-

Non-GAAP Organic revenue

$

766.0

(4.4)%

$

742.6

$

707.4

(5.0)%

$

684.5

$

58.6

3.0%

$

58.1

Three Months Ended
March 31,

2026

2025

Net cash provided by operating activities

$

71.2

$

65.0

Non-GAAP adjustments:

Purchases of property, plant and equipment

(24.2

)

(26.0

)

Non-GAAP free cash flow

$

47.0

$

39.0

Bruker Corporation

PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

(in millions)

  March 31,
2026

December 31,
2025

ASSETS

Current assets:

Cash and cash equivalents

$

133.4

$

298.8

Accounts receivable, net

542.7

544.9

Inventories

1,121.5

1,094.6

Other current assets

306.0

274.2

Total current assets

2,103.6

2,212.5

Property, plant and equipment, net

719.6

744.8

Goodwill, intangibles, net and other long-term assets

3,307.5

3,284.1

Total assets

$

6,130.7

$

6,241.4

LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS’ EQUITY

Current liabilities:

Current portion of long-term debt and finance lease obligations

$

8.4

$

16.6

Accounts payable

269.1

215.9

Deferred revenue and customer advances

479.7

441.3

Other current liabilities

597.9

605.4

Total current liabilities

1,355.1

1,279.2

Long-term debt

1,662.9

1,852.5

Other long-term liabilities

609.9

599.4

Redeemable noncontrolling interests

35.8

36.8

Total shareholders' equity

2,467.0

2,473.5

Total liabilities, redeemable noncontrolling interests and shareholders' equity

$

6,130.7

$

6,241.4

Bruker Corporation

PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

(in millions)

  Three Months Ended
March 31,

2026

2025

Cash flows from operating activities:

Consolidated net income

$

15.7

$

16.8

Adjustments to reconcile consolidated net income to cash flows from operating activities:

Depreciation and amortization

58.3

50.4

Other non-cash expenses, net

21.4

(11.5

)

Changes in operating assets and liabilities, net of acquisitions and divestitures:

Accounts payable and accrued expenses

11.2

26.4

Inventories

(47.2

)

(28.4

)

Other changes in operating assets and liabilities, net

11.8

11.3

Net cash provided by operating activities

71.2

65.0

Cash flows from investing activities:

Purchases of property, plant and equipment

(24.2

)

(26.0

)

Cash paid for acquisitions, net of cash acquired

(16.0

)

(1.1

)

Other investing activities, net

0.5

1.0

Net cash used in investing activities

(39.7

)

(26.1

)

Cash flows from financing activities:

Repayments of revolving lines of credit

—

(167.9

)

Proceeds from revolving lines of credit

—

139.9

Repayment of long-term debt

(181.3

)

(7.7

)

Proceeds from long-term debt

—

2.9

Payment of dividends to Series A Mandatory Convertible Preferred Shareholders

(11.0

)

—

Payment of dividends to common shareholders

(7.6

)

(7.7

)

Repurchase of common stock

—

(10.0

)

Other financing activities, net

(5.0

)

(0.7

)

Net cash used in financing activities

(204.9

)

(51.2

)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

7.9

13.3

Net increase (decrease) in cash, cash equivalents and restricted cash

(165.5

)

1.0

Cash, cash equivalents and restricted cash at beginning of period

303.1

186.7

Cash, cash equivalents and restricted cash at end of period

$

137.6

$

187.7

Bruker Corporation (BRKR) Q1 2026 Earnings Call Transcript

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world's highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) methods for cancer and neuroscience research, where characterization of tissue micro.

At ASMS, [url="]Bruker Corporation[/url] (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separati

At ASMS, [url="]Bruker Corporation[/url] (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, susta

A month has gone by since the last earnings report for Bruker (BRKR - Free Report) . Shares have added about 37.1% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Bruker due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.

Bruker Tops on Q1 Earnings & RevenuesBruker Corporation posted first-quarter 2026 adjusted earnings of 31 cents per share, down 34% year over year. The figure topped the Zacks Consensus Estimate by 33.62%. Quarterly revenues rose 2.7% year over year to $823.4 million and surpassed the consensus mark by 2.91%.

In the quarter, acquisitions contributed 2.6% to the top line, and foreign exchange provided a 4.5% tailwind, while organic revenues decreased 4.4% year over year. The Bruker Scientific Instruments (“BSI”) segment’s bookings grew organically at a high-single-digit rate, and BSI’s book-to-bill stayed above 1.0X for a third straight quarter.

CALID Leads Bruker’s Segment Results

Within the BSI segment, BioSpin revenues were $197.5 million in the first quarter, compared with $207.8 million a year ago. CALID revenues rose to $316.3 million from $280.1 million, while Nano revenues declined to $246.0 million from $256.6 million.

The Bruker Energy & Supercon Technologies (“BEST”) segment delivered $66.9 million of revenues versus $59.3 million in the prior-year quarter, while eliminations were $(3.3) million.

BRKR’s Regional Results Point to Europe as a Bright Spot

Geographically, Europe was the standout, with revenues of $321.6 million, up from $285.2 million in the prior-year quarter. The United States rose to $221.9 million from $217.4 million.

Asia Pacific revenue softened to $208.7 million from $232.6 million, while revenues in the “Other” category increased to $71.2 million from $66.2 million. The mix underscores why headline growth did not fully reflect underlying demand trends across regions.

BRKR’s Margin Performance Weakens Year Over Year

Bruker’s gross profit declined 2.9% year over year to $379.8 million in the first quarter of 2026. Gross margin contracted 269 basis points (bps) to 46.1% as the cost of revenues increased 8.1%.

Operating expenses moved higher. SG&A expenses rose 7.4% year over year to $242.1 million, while R&D expenses increased 4.3% to $101.3 million.

On an adjusted basis, operating income was $84.2 million, down 17.2% year over year, and the operating margin decreased 250 bps to 10.2%.

Management attributed the year-over-year margin pressure primarily to volume and mix, with additional headwinds from foreign exchange and tariffs, partly offset by cost-savings actions.

BRKR’s Cash Flow Rises as Debt Paydown Drives Cash Lower

Cash generation improved year over year. Operating cash flow was $71.2 million, up from $65.0 million, while capital spending was $24.2 million. This supported adjusted free cash flow of $47.0 million compared with $39.0 million in the year-ago quarter.

Bruker ended the quarter with $133.4 million of cash and cash equivalents compared with $298.8 million at the end of 2025. The company paid down $181.3 million of long-term debt during the quarter, and long-term debt stood at $1.66 billion as of March 31, 2026.

Bruker Reaffirms 2026 Outlook

Bruker reaffirmed its full-year 2026 outlook. The company continues to expect revenues of $3.57-$3.60 billion, implying 4%-5% reported growth, including 1%-2% organic growth, about 1.5% from M&A and an estimated 1.5% foreign-currency tailwind.

On the bottom line, Bruker maintained its adjusted earnings view of $2.10-$2.15 per share, calling for 15%-17% growth from the 2025 levels. Management’s framework includes an approximate $0.15 headwind from currency translation and targets 250-300 basis points of adjusted operating margin expansion for the year.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in estimates revision.

The consensus estimate has shifted -11.54% due to these changes.

VGM ScoresAt this time, Bruker has a subpar Growth Score of D, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for value investors.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Bruker has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.

Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript